

Yoshihisa Kurasawa*, Tomoyoshi Hosaka, Kazue Ikeda, Yuko Matsumoto,
Aiko Ishikura and Atsushi Takada

School of Pharmaceutical Sciences, Kitasato University,
Shirokane, Minato-ku, Tokyo 108, Japan

Ho Sik Kim

Department of Chemistry, Hysung Women's University, Gyongsan 713-900, Korea

Yoshihisa Okamoto

Division of Chemistry, College of Liberal Arts and Sciences, Kitasato University,
Kitasato, Sagami-hara, Kanagawa 228, Japan


Received December 28, 1993

The 3-(arylhydrazono)methyl-2-oxo-1,2-dihydroquinoxalines **9-11** were synthesized by the reaction of the quinoxalines **6-8** with various *p*-substituted benzenediazonium salts. Compounds **9-11** showed the tautomeric equilibria between the hydrazone imine **A** and diazenyl enamine **B** forms in dimethyl sulfoxide media. The substituent effect on the tautomer ratios of **A** to **B** was studied by the nmr spectroscopy to clarify that the presence of the ester group R^2 on the hydrazone carbon and electron-donating *p*-substituent R^1 on the side chain benzene ring exhibited a tendency to increase the ratios of the tautomer **A**.

J. Heterocyclic Chem., **31**, 527 (1994).


In a previous paper [1], we reported the synthesis of the side-chained quinoxaline derivatives **1a-d** (Chart 1), whose nmr spectral data showed the tautomeric equilibria between the hydrazone imine **A** and diazenyl enamine **B** forms (Scheme 1) in trifluoroacetic acid and/or dimethyl sulfoxide media. Moreover, the elevation of temperature in the nmr measurement increased the ratios of the tautomer **B** (temperature dependence), and the tautomer ratios of **A** to **B** fluctuated in a series of mixed trifluoroacetic acid/dimethyl sulfoxide media (solvent effect).

compounds also provided no clue for the elucidation of the substituent effects. These results suggested that the setup of the substituents in compounds **1-5** was not suitable for the above purposes. Accordingly, we synthesized




However, the data on the substituent effect could not be obtained from the nmr spectra of compounds **1a-d**. On the other hand, we have already reported the synthesis of the side-chained quinoxaline derivatives **2-5** together with the tautomeric equilibria between the **A** and **B** forms (Scheme 2, Table 1) [2-5], although the nmr spectral data of these

Scheme 1




the side-chained quinoxalines **9-11** having various substituents R^1 , R^2 and R^3 (Scheme 3) in order to study the substituent effects on the tautomer ratios of **A** to **B**. Especially, the electron-withdrawing or electron-donating groups were installed in the *p*-position of the side chain benzene ring. As the result, we found that the presence of an electron-withdrawing group in R^2 exhibited a tendency to augment the ratios of the tautomer **A**, and the existence of an electron-withdrawing group in R^1 represented a tendency to increase the ratios of the tautomer **B**. This paper describes the synthesis of novel quinoxaline derivatives **9-11** and the substituent effects on the tautomer ratios between the hydrazone imine **A** and diazenyl enamine **B** forms. The substituents in the side chain benzene ring were limited to the *p*-position in this paper.

Scheme 2



Scheme 3



The reaction of 3-methoxycarbonylmethylene-1-methyl-2-oxo-1,2,3,4-tetrahydroquinoxaline **6** [6] or 3-methoxycarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline **7** [7] with *p*-methyl- or *p*-nitrobenzenediazonium acetate gave 1-methyl-2-oxo-3-[α -(*p*-tolylhydrazono)methoxycarbonylmethyl]-1,2-dihydroquinoxaline **9a**, 1-methyl-3-[α -(*p*-nitrophenylhydrazono)methoxycarbonylmethyl]-2-oxo-1,2-dihydroquinoxaline **9b**, 2-oxo-3-[α -(*p*-tolylhydrazono)methoxycarbonylmethyl]-1,2-dihydroquinoxaline **10a** or 3-[α -(*p*-nitrophenylhydrazono)methoxycarbonylmethyl]-2-oxo-1,2-dihydroquinoxaline **10b**, respectively (Scheme 3). The reaction of 3-

methyl-2-oxo-1,2-dihydroquinoxaline **8** with *p*-methyl-, *p*-nitro-, *p*-ethyl- or *p*-ethoxycarbonylbenzenediazonium acetate afforded 2-oxo-3-(*p*-tolylhydrazono)methyl-1,2-dihydroquinoxaline **11a**, 3-(*p*-nitrophenylhydrazono)methyl-2-oxo-1,2-dihydroquinoxaline **11b**, 3-(*p*-ethylphenylhydrazono)methyl-2-oxo-1,2-dihydroquinoxaline **11c** or 3-(*p*-ethoxycarbonylphenylhydrazono)methyl-2-oxo-1,2-dihydroquinoxaline **11d**, respectively.

The hydrazone NH (tautomer **A**) and N₄-H (tautomer **B**) proton signals and/or the hydrazone CH (tautomer **A**) and diazenyl CH (tautomer **B**) proton signals in compounds **2-5** (Table 1) have been empirically assigned in

Chart 2




Table 1
NMR Spectral Data for Compounds 2-5

Compound	Tautomer Ratio		Chemical Shift (δ ppm)			
	A	B	Hydrazone NH A Form	N ₄ -H B Form	Hydrazone CH A Form	Diazenyl CH B Form
2a (<i>o</i> -Cl)	67	33	14.35	12.45	--	--
2b (<i>p</i> -Cl)	83	17	11.45	11.97	--	--
3a (<i>o</i> -Cl)	50	50	14.22	12.42	--	--
3b (<i>p</i> -Cl)	80	20	11.18	11.95	--	--
4a (<i>o</i> -Cl)	82	18	13.72	12.53	--	--
4b (<i>p</i> -Cl)	89	11	11.17	11.90	--	--
4c (<i>m</i> -Cl)	91	9	11.15	11.87	--	--
5a (<i>o</i> -Cl)	100	0	14.75	--	7.87	--
5b (<i>p</i> -Cl)	67	33	14.53	11.26	7.73	8.37
5c (<i>m</i> -Cl)	67	33	14.45	11.33	7.78	8.40

Table 2
NMR Spectral Data for Compounds 9-11


Compound	R ¹	R ²	R ³	Tautomer Ratio		Chemical Shift (δ ppm)					
				A	B	Hydrazone NH A Form	N ₄ -H B Form	C ₅ -H A Form	C ₅ -H B Form	Hydrazone CH A Form	Diazenyl CH B Form
9a	Me	COOMe	Me	100	0	11.00	--	7.94	--	--	--
9b	NO ₂	COOMe	Me	100	0	11.29	--	7.96	--	--	--
10a	Me	COOMe	H	100	0	11.13	--	7.88	--	--	--
10b	NO ₂	COOMe	H	100	0	11.36	--	7.89	--	--	--
11a	Me	H	H	67	33	14.53	11.15	8.02	7.77	7.68	8.32
11c	Et	H	H	67	33	14.53	11.17	7.99	7.77	7.68	8.33
11d	COOEt	H	H	46	54	14.49	11.54	8.04	7.81	7.79	8.44
11b	NO ₂	H	H	30	70	14.53	11.90	8.10	7.82	7.86	8.49

comparison with the chemical shifts of other similar compounds. These empirical assignments in compounds 2-5 were found to be in good agreement with the assignments of the hydrazone NH, N₄-H, hydrazone CH and diazenyl CH proton signals in compounds 9-11 (Table 2), which were supported by the HMBC and NOE spectral data (Charts 2-6).

Namely, the HMBC spectra of compound 9a exhibited a correlation between the *o*-C carbon (δ 114.0 ppm) and the hydrazone NH proton (δ 11.00 ppm), between the side chain benzene C₁ carbon (δ 140.9 ppm) and the hydrazone NH proton (δ 11.00 ppm) and between the hydrazone carbon (δ 127.6 ppm) and the hydrazone NH proton (δ 11.00 ppm) (Chart 2, Table 2). In addition, the NOE was observed between the hydrazone NH and *o*-H proton signals in compounds 9a and 9b (Chart 3). Since compounds 9a and 9b are composed of a single tautomer, the above data show the predominance of the species 9a-A and 9b-A. Similar NOE spectral data was obtained for compound 4b (Chart 2). Thus, the hydrazone NH proton signals of the *p*-chloro and the *m*-chloro series of compounds 2b, 3b, 4b, 4c (δ 11.45-11.15 ppm) and the *p*-methyl and the *p*-nitro series of compounds 9a,b, 10a,b (δ 11.36-11.00 ppm), both having the oxadiazole ring or ester group on

the hydrazone carbon, were found to appear in a similar magnetic field (Table 3). Accordingly, the signals at δ 11.97-11.87 ppm were assigned to the N₄-H protons of the tautomer B in the *p*-chloro and the *m*-chloro series of compounds 2b, 3b, 4b, 4c (Tables 1,3).

Chart 3



On the other hand, the HMBC spectra of compound 11a represented the correlation between the *o*-C carbon (δ 114.1 ppm) and hydrazone NH proton (δ 14.53 ppm) and between the side chain benzene C₁ carbon (δ 141.0 ppm)

Table 3
NMR Spectral Data for Compounds 2-5 and 9-11


Compound A Form	R ¹	R ²	Hydrazone NH B Form	Chemical Shift (δ ppm) N ₄ -H	Hydrazone CH	Diazenyl CH
	B Form	A Form				
2a	<i>o</i> -Cl	Oxdzl [a]				
3a	<i>o</i> -Cl	MeOxdzl [b]	14.35-13.72	12.53-12.42	--	--
4a	<i>o</i> -Cl	COOMe				
2b	<i>p</i> -Cl	Oxdzl				
3b	<i>p</i> -Cl	MeOxdzl				
4b	<i>p</i> -Cl	COOMe	11.45-11.15	11.97-11.87	--	--
4c	<i>m</i> -Cl	COOMe				
9a	<i>p</i> -Me	COOMe				
9b	<i>p</i> -NO ₂	COOMe				
10a	<i>p</i> -Me	COOMe	11.36-11.00	--	--	--
10b	<i>p</i> -NO ₂	COOMe				
5a	<i>o</i> -Cl	H				
5b	<i>p</i> -Cl	H	14.75-14.45	11.33-11.26	7.87-7.73	8.40-8.37
5c	<i>m</i> -Cl	H				
11a	<i>p</i> -Me	H				
11b	<i>p</i> -NO ₂	H				
11c	<i>p</i> -Et	H	14.53-14.49	11.90-11.15	7.86-7.68	8.49-8.32
11d	<i>p</i> -COOEt	H				

[a] 1,3,4-Oxadiazol-2-yl. [b] 5-Methyl-1,3,4-oxadiazol-2-yl.

and hydrazone NH proton (δ 14.53 ppm) as well as the correlation between the C₂=O carbon and the N₁-H proton, between the C₂=O carbon and the hydrazone CH proton and between the C₂=O carbon and the diazenyl CH proton (Chart 4). These data indicated that the hydrazone

of the tautomers A and B in compounds 5a-c and 11a-d (Charts 5, 6, Tables 1-3), wherein the hydrazone NH, N₄-

Chart 4



11a - A

Hydrazone NH (δ 14.53)
Hydrazone CH (δ 7.68)
N₁-H (δ 12.55)
Benzene C₁ (δ 141.0)
 α -C (δ 114.1)
C₂=O (δ 149.5)


11a - B

Diazenyl CH (δ 8.32)
N₁-H (δ 12.35)
C₂=O (δ 150.9)

HMBC Spectral Data for Compound 11a

NH proton signals appeared at δ 14.75-14.45 ppm in compounds 5a-c and 11a-d (Tables 1-3). In general, the N₄-H proton signals did not appear at a lower magnetic field than δ 14 ppm [8-14]. Consequently, the C₅-H proton signals of the tautomer A were observed to appear at a lower magnetic field than those of tautomer B [1]. Thus, the above results supported the assignment for the signal pairs

Chart 5




11a - A

Hydrazone NH (δ 14.53)
Hydrazone CH (δ 7.68)
 α -H (δ 7.33)
C₅-H (δ 8.02)


11a - A

2.2%
5.1%



11a - B

N₄-H (δ 11.15)
Diazenyl CH (δ 8.32)
 α -H (δ 7.18)
C₅-H (δ 7.77)



11a - B

NOE Spectral Data (%) for Compound 11a

C_5H_4N) in boiling *n*-butanol resulted in the formation of the corresponding compounds **4a-c** in good yield. The structure of the products was established from their spectral characteristics which indicated that in addition to heterocyclization, deacetylation had taken place. Heating **4a-c** in acetic anhydride led to the formation of their acetyl derivatives **5a-c**.

For the preparation of the 1-methyl analog, **7**, compound **3** was treated with hydrazine to form **6** which on treatment with boiling acetic anhydride afforded **7**. On the other hand, treatment of **6** with acetylacetone yielded compound **8**. The structural assignment of **8** was confirmed by ^{13}C -nmr analysis.

Compound **3** was converted to tetrazolo[1,5-*a*]pyridazine **9** by the reaction of the former with sodium azide in *N,N*-dimethylformamide. The structure of **9** was supported by infrared spectroscopy.

Currently, the products isolated herein are being screened for biological activity.

EXPERIMENTAL

Melting points were determined on a Mel-Temp melting point apparatus and are reported uncorrected. Analytical tlc was performed using ascending technique with EM silica gel 60 F₂₅₄ precoated on plastic sheets. The ir spectra were obtained on Unicam SP 1025 spectrometer, and were calibrated against the 1601 cm^{-1} band of polystyrene. The nmr spectra were recorded on Bruker AC-250 or Nicolet NT 300 MHz spectrometers. Chemical shifts are reported in parts per million downfield from internal tetramethylsilane. Apparent coupling constants (*J*) are given in Hertz (Hz). A Hewlett-Packard 5995 Gas Chromatograph/Mass Spectrometer was used to record eims data at 70 eV. Elemental analyses were performed in the Chemistry Department, Faculty of Science, Alexandria, and/or Ain-Shames Universities, Egypt.

1-Aryl-4-(hydroxymethyl)-1-phenylpyrazol-3-yl][1,2,4]triazolo[4,3-*a*]quinoxaline (**4**).

General Procedure.

A solution of **3** (2.6 mmole) and the desired aroylhydrazine (5.9 mmole) in butanol (20 ml) was heated under reflux for 8 hours. The reaction mixture was concentrated and the desired product that separated out was filtered off and recrystallized from ethanol or purified by flash column chromatography on silica gel using ethyl acetate as an eluent (Table).

4-[5-(Acetoxymethyl)-1-phenylpyrazol-3-yl]-1-aryl[1,2,4]triazolo[4,3-*a*]quinoxaline (**5**).

General Procedure.

A solution of **4** (0.72 mmole) in acetic anhydride (5 ml) was heated under reflux for 1 hour. The mixture was then cooled and poured onto crushed ice. The product was filtered off, washed

with water, dried, and recrystallized from ethanol (Table).

2-Hydrazino-3-[5-hydroxymethyl]-1-phenylpyrazol-3-yl]quinoxaline (**6**).

A suspension of **3** (0.3 g, 0.79 mmole) in hydrazine hydrate (1 ml) was heated under reflux for 1 hour. The resulting product was filtered, washed with ethanol, and dried to yield 0.25 g (95%), mp 224-226°; ir (potassium bromide): 3311, 3213, 3138 cm^{-1} ; 1H -nmr (300 MHz, DMSO- d_6): δ 4.62 (d, *J* = 5.52 Hz, 2 H, CH₂O), 4.77 (br s, 2H, NH₂), 5.70 (t, *J* = 5.52 Hz, 1H, OH), 7.35-7.90 (m, 10H, arom), 9.44 (s, 1H, NH).

Anal. Calcd. for C₁₈H₁₆N₆O: C, 65.04; H, 4.85; N, 25.29. Found: C, 65.24; H, 4.91; N, 25.32.

4-[5-(Acetoxymethyl)-1-phenylpyrazol-3-yl]-1-methyl[1,2,4]triazolo[4,3-*a*]quinoxaline (**7**).

A solution of **6** (0.3 g, 0.90 mmole) in acetic anhydride (5 ml) was refluxed for 1 hour. The mixture was allowed to cool to room temperature and was then poured onto crushed ice. The product was collected by filtration, washed with water and dried to yield 0.3 g (83%) mp 214-215°; ir (potassium bromide): 1745 (COO) cm^{-1} ; 1H -nmr (250 MHz, DMSO- d_6): δ 2.10 (s, 3H, CH₃CO), 3.23 (s, 3H, CH₃), 5.20 (s, 2H, CH₂O), 7.48-7.65, 8.11, 8.21, 8.30 (m, s, m, m, 10H arom).

Anal. Calcd. for C₂₂H₁₈N₆O₂: C, 66.32; H, 4.55; N, 21.10. Found: C, 66.11; H, 4.39; N, 20.86.

3-[5-(Hydroxymethyl)-1-phenylpyrazol-3-yl]-2-(3,5-dimethylpyrazol-1-yl)quinoxaline (**8**).

A solution of **6** (0.5 g, 1.5 mmole) in acetylacetone (5 ml) was refluxed for 1 hour. The mixture was allowed to cool to room temperature and the precipitate was filtered and crystallized from methanol-benzene to yield 0.54 g (91%), mp 173-174°; ir (potassium bromide): 3245 (OH) cm^{-1} ; 1H -nmr (300 MHz, DMSO- d_6): δ 2.09, 2.31 (2 s, 6H, 2 CH₃), 3.19 (bs, 1H, OH), 4.53 (bs, 2H, CH₂O), 6.04, 6.18 (2s, 2H, proton at 4-positions of the pyrazolyl rings), 7.33-8.29 (5 m, 9H arom); ^{13}C -nmr (75.5 MHz, deuteriochloroform): δ 11.4, 13.5, 55.1, 106.9, 108.5, 124.1, 127.8, 127.9, 128.9, 129.1, 129.3, 130.6, 131.1, 139.3, 140.2, 141.7, 142.2, 143.7, 144.2, 144.8, 147.5, 150.0.

Anal. Calcd. for C₂₃H₂₀N₆O: C, 69.68; H, 5.09; N, 21.20. Found: C, 69.53; H, 4.98; N, 21.37.

4-[5-(Acetoxymethyl)-1-phenylpyrazol-3-yl]tetrazolo[1,5-*a*]quinoxaline (**9**).

A solution of **3** (0.5 g, 1.32 mmole) and sodium azide (0.18 g, 2.76 mmole) in *N,N*-dimethylformamide (20 ml) was heated under reflux for 8 hours. The solution was then cooled and poured into water. The precipitate was filtered and recrystallized from chloroform-ethanol to obtain **9**, (yield 0.42 g (83%) mp 185°; ir (potassium bromide): 1738 cm^{-1} ; 1H -nmr (250 MHz, DMSO- d_6): δ 2.05 (s, 3H, CH₃CO), 5.28 (s, 2H, CH₂O), 7.59-8.63 (m, 10H arom); ms: *m/z* 385 (M⁺, 2), 358 (23); 357 (49), 315 (55), 314 (100), 286 (24), 77 (24).

Anal. Calcd. for C₂₀H₁₅N₇O₂: C, 62.33; H, 3.92; N, 25.44. Found: C, 62.11; H, 3.74; N, 25.18.

to give a clear solution, which was added to a solution of 3-methoxycarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (3 g, 13.4 mmol) in acetic acid (50 ml). The mixture was heated with stirring on a boiling water bath for 1 hour to precipitate a small amount of red needles **10a**. Then, the mixture was cooled in an ice-water bath to precipitate red needles **10a**, which were collected by suction filtration and washed with ethanol to provide an analytically pure sample (1.18 g, 25%), mp 258-259°; ir: ν cm^{-1} 1715, 1650, 1585; ms: m/z 336 (M^+); pmr: 12.58 (brs, 1H, N_1 -H), 11.13 (s, 1H, hydrazone NH), 7.88 (dd, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_5 -H), 7.62 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_7 -H), 7.38 (dd, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_8 -H), 7.36 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_6 -H), 7.16 (d, $J = 8.5$ Hz, 2H, o -H), 7.12 (d, $J = 8.5$ Hz, 2H, m -H), 3.73 (s, 3H, OCH_3), 2.25 (s, 3H, p - CH_3).

Anal. Calcd. for $C_{18}H_{16}N_4O_3$: C, 64.28; H, 4.80; N, 16.66. Found: C, 64.49; H, 4.89; N, 16.96.

3-[α -(*p*-Nitrophenylhydrazono)methoxycarbonylmethyl]-2-oxo-1,2-dihydroquinoxaline **10b**.

A solution of sodium nitrite (2.37 g, 34.4 mmol) in water (30 ml) was added to a suspension of *p*-nitroaniline (4.75 g, 34.4 mmol) in acetic acid (50 ml) with stirring in an ice-water bath to give yellow precipitates, which were added to a solution of 3-methoxycarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (3 g, 13.8 mmol) in acetic acid (50 ml). The mixture was heated with stirring on a boiling water bath for 1 hour to precipitate yellow crystals **10b**, which were collected by suction filtration (3.09 g, 61%). Recrystallization from *N,N*-dimethylformamide/ethanol afforded yellow needles, mp 295-296°; ir: ν cm^{-1} 1730, 1665, 1585; ms: m/z 367 (M^+); pmr: 12.73 (brs, 1H, N_1 -H), 11.36 (brs, 1H, hydrazone NH), 8.23 (d, $J = 9.0$ Hz, 2H, m -H), 7.89 (dd, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_5 -H), 7.66 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_7 -H), 7.41 (dd, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_8 -H), 7.39 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.5$ Hz, 1H, C_6 -H), 7.37 (d, $J = 9.0$ Hz, 2H, o -H), 3.77 (s, 3H, OCH_3).

Anal. Calcd. for $C_{17}H_{13}N_5O_5$: C, 55.59; H, 3.57; N, 19.07. Found: C, 55.63; H, 3.76; N, 18.80.

2-Oxo-3-(*p*-tolylhydrazono)methyl-1,2-dihydroquinoxaline **11a**.

A solution of sodium nitrite (1.47 g, 21.3 mmol) in water (30 ml) was added to a suspension of *p*-toluidine (2.27 g, 21.3 mmol) in acetic acid (50 ml) with stirring in an ice-water bath to give a clear solution, which was added to a solution of 3-methyl-2-oxo-1,2-dihydroquinoxaline (2 g, 12.5 mmol) in acetic acid (50 ml). The mixture was heated with stirring on a boiling water bath for 1 hour to afford a violet clear solution. The solvent was evaporated *in vacuo* to provide an oily residue, which was crystallized from ethanol/water to give orange crystals (1.12 g, 34%). Recrystallization from *N,N*-dimethylformamide/ethanol furnished orange-red needles, mp 298-299°; ir: ν cm^{-1} 1660; ms: m/z 278 (M^+); pmr: (hydrazone imine form A) 14.53 (s, hydrazone NH), 12.55 (s, N_1 -H), 8.02 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.68 (s, hydrazone CH), 7.51 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.36-7.25 (m, C_8 -H and C_6 -H), 7.33 (d, $J = 8.0$ Hz, o -H), 7.17 (d, $J = 8.0$ Hz, m -H), 2.28 (s, p - CH_3); (diazanyl enamine form B) 12.35 (s, N_1 -H), 11.15 (s, N_4 -H), 8.32 (s, diazanyl CH), 7.77 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.45 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.36-7.25 (m, C_8 -H and C_6 -H), 7.18 (d, $J = 8.0$ Hz, o -H), 7.07

(d, $J = 8.0$ Hz, m -H), 2.24 (s, p - CH_3).

Anal. Calcd. for $C_{16}H_{14}N_4O$: C, 69.05; H, 5.07; N, 20.13. Found: C, 68.87; H, 5.08; N, 20.03.

3-(*p*-Nitrophenylhydrazono)methyl-2-oxo-1,2-dihydroquinoxaline **11b**.

A solution of sodium nitrite (2.16 g, 31.3 mmol) in water (30 ml) was added to a suspension of *p*-nitroaniline (4.31 g, 31.3 mmol) in acetic acid (50 ml) with stirring in an ice-water bath to give yellow precipitates, which were added to a solution of 3-methyl-2-oxo-1,2-dihydroquinoxaline (2 g, 12.5 mmol). The mixture was heated with stirring on a boiling water bath for 1 hour to precipitate orange crystals of **11b**, which were collected by suction filtration (2.19 g, 57%). Recrystallization from *N,N*-dimethylformamide/ethanol provided orange needles, mp above 320°; ir: ν cm^{-1} 1660, 1590; ms: m/z 309 (M^+); pmr: (hydrazone imine form A) 14.53 (s, hydrazone NH), 12.54 (brs, N_1 -H), 8.19 (d, $J = 9.0$ Hz, m -H), 8.10 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.86 (s, hydrazone CH), 7.56 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.55 (d, $J = 9.0$ Hz, o -H), 7.39-7.28 (m, C_8 -H and C_6 -H); (diazanyl enamine form B) 12.54 (brs, N_1 -H), 11.90 (brs, N_4 -H), 8.49 (s, diazanyl CH), 8.19 (d, $J = 9.0$ Hz, m -H), 7.82 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.51 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.39-7.28 (m, C_8 -H and C_6 -H), 7.26 (d, $J = 8.0$ Hz, o -H).

Anal. Calcd. for $C_{15}H_{11}N_5O_3$: C, 58.25; H, 3.59; N, 22.65. Found: C, 58.36; H, 3.45; N, 22.39.

3-(*p*-Ethylphenylhydrazono)methyl-2-oxo-1,2-dihydroquinoxaline **11c**.

A solution of sodium nitrite (1.30 g, 18.8 mmol) in water (50 ml) was added to a solution of *p*-ethylaniline (2.27 g, 18.8 mmol) in acetic acid (30 ml) in an ice-water bath to give a clear solution, which was added to a suspension of 3-methyl-2-oxo-1,2-dihydroquinoxaline (2 g, 12.5 mmol) in acetic acid (20 ml)/water (50 ml). The mixture was heated with stirring on a boiling water bath for 20 minutes to afford orange crystals **11c**, which were collected by suction filtration. Recrystallization from *N,N*-dimethylformamide/ethanol furnished orange needles (670 mg, 18%), mp 296-297°; ir: ν cm^{-1} 1650; ms: m/z 292 (M^+); pmr: (hydrazone imine form A) 14.53 (s, hydrazone NH), 12.50 (brs, N_1 -H), 7.99 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.68 (s, hydrazone CH), 7.50 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.33 (d, $J = 8.5$ Hz, o -H), 7.30-7.24 (m, C_8 -H and C_6 -H), 7.13 (d, $J = 8.5$ Hz, m -H), 2.57 (q, $J = 7.0$ Hz, CH_2 of p - CH_2CH_3), 1.17 (t, $J = 7.0$ Hz, CH_3 of p - CH_2CH_3); (diazanyl enamine form B) 12.50 (brs, N_1 -H), 11.17 (s, N_4 -H), 8.33 (s, diazanyl CH), 7.77 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.44 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.30-7.24 (m, C_8 -H and C_6 -H), 7.19 (d, $J = 8.5$ Hz, o -H), 7.09 (d, $J = 8.5$ Hz, m -H), 2.54 (q, $J = 7.0$ Hz, CH_2 of p - CH_2CH_3), 1.16 (t, $J = 7.0$ Hz, CH_3 of p - CH_2CH_3).

Anal. Calcd. for $C_{17}H_{16}N_4O$: C, 69.84; H, 5.52; N, 19.17. Found: C, 69.89; H, 5.58; N, 19.13.

3-(*p*-Ethoxycarbonylphenylhydrazono)methyl-2-oxo-1,2-dihydroquinoxaline **11d**.

A solution of sodium nitrite (1.30 g, 18.8 mmol) in water (50 ml) was added to a solution of ethyl *p*-aminobenzoate (3.10 g, 18.8 mmol) in acetic acid (30 ml) in an ice-water bath to give a yellow suspension, which was added to a suspension of 3-methyl-2-oxo-1,2-dihydroquinoxaline (2 g, 12.5 mmol) in

acetic acid (20 ml)/water (50 ml). The mixture was heated with stirring on a boiling water bath for 20 minutes to afford orange crystals of **11d**, which were collected by suction filtration. Recrystallization from *N,N*-dimethylformamide/ethanol furnished orange needles (910 mg, 22%), mp 288-289°; ir: ν cm^{-1} 1690, 1650; ms: m/z 336 (M^+); pmr: (hydrazone imine form **A**) 14.49 (s, hydrazone NH) 12.53 (brs, N_1 -H), 8.04 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.92 (d, $J = 9.0$ Hz, m -H), 7.79 (s, hydrazone CH), 7.54 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.48 (d, $J = 9.0$ Hz, o -H), 7.33-7.27 (m, C_8 -H and C_6 -H), 4.27 (q, $J = 7.0$ Hz, CH_2 of p - $\text{COOCH}_2\text{CH}_3$), 1.31 (t, $J = 7.0$ Hz, CH_3 of p - $\text{COOCH}_2\text{CH}_3$); (diazanyl enamine form **B**) 12.53 (brs, N_1 -H), 11.54 (s, N_4 -H), 8.44 (s, diazenyl CH), 7.89 (d, $J = 9.0$ Hz, m -H), 7.81 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, C_5 -H), 7.34 (ddd, $J = 8.0$ Hz, $J = 8.0$ Hz, $J = 1.0$ Hz, C_7 -H), 7.33-7.27 (m, C_8 -H and C_6 -H), 7.22 (d, $J = 9.0$ Hz, o -H), 4.26 (q, $J = 7.0$ Hz, CH_2 of p - $\text{COOCH}_2\text{CH}_3$), 1.30 (t, $J = 7.0$ Hz, CH_3 of p - $\text{COOCH}_2\text{CH}_3$).

Anal. Calcd. for $\text{C}_{18}\text{H}_{16}\text{N}_4\text{O}_3$: C, 64.27; H, 4.80; N, 16.66. Found: C, 64.29; H, 4.87; N, 16.67.

REFERENCES AND NOTES

[1] Y. Kurasawa, A. Ishikura, K. Ikeda, T. Hosaka, Y.

Matsumoto, A. Takada, H. S. Kim and Y. Okamoto, *J. Heterocyclic Chem.*, **31**, 233 (1994).

[2] Y. Kurasawa, M. Muramatsu, Y. Okamoto and A. Takada, *J. Heterocyclic Chem.*, **23**, 637 (1986).

[3] Y. Kurasawa, M. Muramatsu, K. Yamazaki, S. Tajima, Y. Okamoto and A. Takada, *J. Heterocyclic Chem.*, **23**, 1245 (1986).

[4] Y. Kurasawa, K. Yamazaki, S. Tajima, Y. Okamoto and A. Takada, *J. Heterocyclic Chem.*, **23**, 957 (1986).

[5] Y. Kurasawa, M. Muramatsu, K. Yamazaki, S. Tajima, Y. Okamoto and A. Takada, *J. Heterocyclic Chem.*, **23**, 1379 (1986).

[6] D. D. Chapman, *J. Chem. Soc.*, 806 (1966).

[7] Y. Iwanami, *Nippon Kagaku Zasshi*, **83**, 593 (1962).

[8] Y. Kurasawa, Y. Moritaki and A. Takada, *Heterocycles*, **19**, 1619 (1982).

[9] Y. Kurasawa, Y. Moritaki and A. Takada, *Synthesis*, 238 (1983).

[10] Y. Kurasawa, Y. Moritaki, T. Ebukuro and A. Takada, *Chem. Pharm. Bull.*, **31**, 3897 (1983).

[11] Y. Kurasawa, K. Suzuki, S. Nakamura, K. Moriyama and A. Takada, *Heterocycles*, **22**, 695 (1984).

[12] Y. Kurasawa, S. Nakamura, K. Moriyama, K. Suzuki and A. Takada, *Heterocycles*, **22**, 1189 (1984).

[13] Y. Kurasawa, S. Shimabukuro, Y. Okamoto and A. Takada, *Heterocycles*, **23**, 65 (1985).

[14] Y. Kurasawa, M. Ichikawa, I. Kamata, Y. Okamoto and A. Takada, *Heterocycles*, **23**, 281 (1985).